Login to Your Account



BIO CEO & INVESTOR CONFERENCE

Amyloid beta debate still RAGE[s], though AD space finally advancing

By Jennifer Boggs
Managing Editor

Tuesday, February 9, 2016

NEW YORK – Last year's big win by Biogen Inc. with Alzheimer's disease candidate aducanumab, the first potentially disease-modifying drug to hit its prespecified endpoint in a proof-of-concept study, restored optimism to a space that had been riddled with failure and reaffirmed faith in the amyloid beta (abeta) hypothesis – at least for some. (See BioWorld Today, March 23, 2015, and April 27, 2015.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription